Success Metrics

Clinical Success Rate
77.0%

Based on 241 completed trials

Completion Rate
77%(241/313)
Active Trials
61(13%)
Results Posted
53%(128 trials)
Terminated
72(15%)

Phase Distribution

Ph phase_4
68
14%
Ph not_applicable
48
10%
Ph phase_1
64
13%
Ph phase_2
170
36%
Ph early_phase_1
8
2%
Ph phase_3
100
21%

Phase Distribution

72

Early Stage

170

Mid Stage

168

Late Stage

Phase Distribution458 total trials
Early Phase 1First-in-human
8(1.7%)
Phase 1Safety & dosage
64(14.0%)
Phase 2Efficacy & side effects
170(37.1%)
Phase 3Large-scale testing
100(21.8%)
Phase 4Post-market surveillance
68(14.8%)
N/ANon-phased studies
48(10.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.4%

241 of 333 finished

Non-Completion Rate

27.6%

92 ended early

Currently Active

61

trials recruiting

Total Trials

475

all time

Status Distribution
Active(71)
Completed(241)
Terminated(92)
Other(71)

Detailed Status

Completed241
Terminated72
unknown71
Recruiting40
Active, not recruiting21
Withdrawn20

Development Timeline

Analytics

Development Status

Total Trials
475
Active
61
Success Rate
77.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 18 (1.7%)
Phase 164 (14.0%)
Phase 2170 (37.1%)
Phase 3100 (21.8%)
Phase 468 (14.8%)
N/A48 (10.5%)

Trials by Status

completed24151%
not_yet_recruiting102%
active_not_recruiting214%
unknown7115%
recruiting408%
terminated7215%
withdrawn204%

Recent Activity

Clinical Trials (475)

Showing 20 of 475 trialsScroll for more
NCT06717347Phase 3

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Recruiting
NCT06317662Phase 2

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Recruiting
NCT06670521Phase 2

Corticosteroids for Post-Extubation Dysphagia

Recruiting
NCT06474273Phase 3

TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Recruiting
NCT05986422Phase 2

Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)

Terminated
NCT02166463Phase 3

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Active Not Recruiting
NCT05039619Phase 2

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

Recruiting
NCT03007147Phase 3

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Active Not Recruiting
NCT02784210Phase 2

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Recruiting
NCT04544436Phase 3

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Active Not Recruiting
NCT03898154Phase 4

Perioperative Glucocorticoid Administration in the Treatment of Adult Distal Radius Fractures

Terminated
NCT04408625Phase 1

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Active Not Recruiting
NCT05842681Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Recruiting
NCT07554885Not Applicable

Nutritional Therapy Plus Corticosteroids for Immune Checkpoint Inhibitor-Related Pneumonitis

Not Yet Recruiting
NCT07412470Phase 2

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

Recruiting
NCT06970743Phase 3

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors

Recruiting
NCT07070882Phase 1

Oral Steroid Taper After Total Knee Arthroplasty

Active Not Recruiting
NCT05925166Not Applicable

Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout

Completed
NCT01624805Phase 2

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Recruiting
NCT07052929Phase 1

Study of ASP2957 in Male Participants With X-linked Myotubular Myopathy Who Need Ventilators

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
475